Topics:

HER2-Positive Breast Cancer

Two studies indicate that older women with trastuzumab-treated breast cancer and those who undergo radiation to the left chest wall may be at risk for increased rates of cardiotoxicity.

HER2-Positive Breast Cancer

A phase I study of intermittent oral lapatinib in patients with HER2-amplified breast cancer escalated up to 7,000 mg per day (shown to be effective in mouse models), found that plasma concentrations of the drug did not increase proportionately with the oral dose, impeding clinical translation of this method.

Older age and comorbidities were associated with a higher risk of failing to complete trastuzumab therapy in a new study of older women with early-stage breast cancer, where nearly 20% failed to complete the treatment.

This article discusses the development of pertuzumab to date, with a particular focus on the accelerated approval decision. We highlight the need to identify reliable biomarkers of sensitivity and resistance to HER2-targeted therapy, which would make possible the individualization of treatment for patients with HER2-positive breast cancer.

Contrary to some expectations, getting accelerated approval for neoadjuvant therapy does not look easy, and the pertuzumab story may be the exception that proves the rule.

At this point, there is expectation that pertuzumab given in the neoadjuvant setting will improve long-term efficacy. We welcome the opportunity to include pertuzumab in the neoadjuvant regimen of patients with HER2-positive breast cancer.

Women who developed a rash early in their treatment for HER2-positive breast cancer with lapatinib were more likely to go on to have pathologic complete response compared to those who did not get a rash, according to the results of an unplanned analysis of data from the NeoALTTO trial.

Concurrent administration of trastuzumab and anthracyclines resulted in a similar rate of pathologic complete response when compared to sequential administration in women with HER2-positive breast cancer, according to the results of a new study.

Pages

Subscribe to
Please Wait 20 seconds or click here to close